Immunotherapy in HCC: aetiology matters

2026/04/01 by Irene Oi‐Lin Ng, Guoyue Lyu · 1 voice
Medicine · #Cancer Immunotherapy and Biomarkers #Chronic Lymphocytic Leukemia Research #Lymphoma Diagnosis and Treatment

paper · doi:10.1136/egastro-2026-100465

openalex publication_date 2026/04/01 · openalex created_date 2026/05/30 · openalex updated_date 2026/07/22

Abstract

The therapeutic landscape of advanced hepatocellular carcinoma (HCC) has undergone a paradigm shift with the advent of immune checkpoint blockade (ICB).

Discussions

• 📢 New Perspective in #eGastroenterology 🔄 Prof. Irene Oi-Lin Ng and Prof. Guoyue Lyu highlight that #HCC is not a uniform disease—its aetiology may shape the tumour immune microenvironment and resp [bsky, 1 points, 0 comments]

Related

• Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma
• Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions
• The current landscape of therapies for hepatocellular carcinoma
• Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
• Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma